PROGNOSTIC VALUE OF MOLECULAR GENETIC MARKERS IN KIDNEY CANCER PATIENTS RECEIVING TARGETED THERAPY

Authors: Peters M.V.¹, Shevchenko V.E.¹, Matveev V.B.¹, Volkova M.I.¹, Kalinin S.A.¹, Mikhailenko D.M.², Zaletayev D.V.²
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
2. Research Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University
Issue: Vol 7, No 4 (2011)
Pages: 24-31
Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
Published: 30.12.2011
URL: https://oncourology.abvpress.ru/oncur/article/view/185
DOI: https://doi.org/10.17650/1726-9776-2011-7-4-24-31
ID: 185

Cite item

Full Text

targeted therapy, VHL gene alterations, plasma markers, prognostic value

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Author for correspondence.
Email: mariapetersomega0803@mail.ru
Russian Federation

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Research Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University

Research Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University

Supplementary Files

Action

1. JATS XML